BG63183B1 - Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации - Google Patents

Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации

Info

Publication number
BG63183B1
BG63183B1 BG097664A BG9766493A BG63183B1 BG 63183 B1 BG63183 B1 BG 63183B1 BG 097664 A BG097664 A BG 097664A BG 9766493 A BG9766493 A BG 9766493A BG 63183 B1 BG63183 B1 BG 63183B1
Authority
BG
Bulgaria
Prior art keywords
specific
cell populations
pathogenic
vaccine
vaccine against
Prior art date
Application number
BG097664A
Other languages
English (en)
Other versions
BG63183B2 (bg
Inventor
Mark Howell
Steven Brostoff
Dennis Carlo
Original Assignee
The Immune Response Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Immune Response Corporation filed Critical The Immune Response Corporation
Publication of BG63183B2 publication Critical patent/BG63183B2/bg
Publication of BG63183B1 publication Critical patent/BG63183B1/bg

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до ваксини и средства за ваксиниране на гостоприемник с цел предотвратяване или контролиране на специфични Т-клетъчно медиирани патологии. Ваксината е съставена от антиидиотипни антитела, които са вътрешни отражения на сегмент от Т-клетъчния рецептор (TCR), разположен на повърхността на патогенните Т-клетки. Ваксината се прилага на гостоприемника по начин, който включва имунен отговор, насочен спрямо TCR на патогенните клетки. Този имунен отговор регулира или отстранява патогенните Т-клетки, като по този начин елиминира патогенезата. Изобретението се отнася и до средства за определяне на подходяща аминокиселинна последователност за такава ваксина.@
BG097664A 1992-07-16 1993-04-26 Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации BG63183B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91464292A 1992-07-16 1992-07-16

Publications (2)

Publication Number Publication Date
BG63183B2 BG63183B2 (bg) 2001-05-31
BG63183B1 true BG63183B1 (bg) 2001-05-31

Family

ID=91081612

Family Applications (1)

Application Number Title Priority Date Filing Date
BG097664A BG63183B1 (bg) 1992-07-16 1993-04-26 Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации

Country Status (1)

Country Link
BG (1) BG63183B1 (bg)

Also Published As

Publication number Publication date
BG63183B2 (bg) 2001-05-31

Similar Documents

Publication Publication Date Title
Yang et al. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection
Dong-Ji et al. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses
Tarkkanen et al. Contact of lymphocytes with Helicobacter pylori augments natural killer cell activity and induces production of gamma interferon
Riggs Recent advances in cryptosporidiosis: the immune response
Köllner et al. Evaluation of immune functions of rainbow trout (Oncorhynchus mykiss)—how can environmental influences be detected?
Ober et al. Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+ CD8+ memory T-helper cells in swine
Halse et al. Increased frequency of cells secreting interleukin‐6 and interleukin‐10 in peripheral blood of patients with primary Sjögren's syndrome
BG95337A (bg) Ваксиниране и методи срещу заболявания,резултат от патогенни отговори на т-клетъчно специфични популации
WO1992012996A3 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
NO995458D0 (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
Hassan et al. DNA vaccination with a gene encoding Toxoplasma gondii Deoxyribose Phosphate Aldolase (TgDPA) induces partial protective immunity against lethal challenge in mice
DK96493D0 (da) Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DK0606217T4 (da) CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
ES2307496T4 (es) Composiciones de vacuna, antígenos y péptidos de VIH
Chen et al. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response
Manca et al. The naive repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV.
Heath et al. Conjugation of interferon-gamma to antigen enhances its adjuvanticity.
NO923778D0 (no) Multippel sklerose t-celle-reseptor
NZ502144A (en) Multi-subtype FIV vaccines
Cohen et al. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
WO1993012814A3 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
ATE109512T1 (de) Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
Wang et al. Protective immunity against acute toxoplasmosis in BALB/c mice induced by a DNA vaccine encoding Toxoplasma gondii elongation factor 1-alpha
Vestergaard Production of antiserum against a specific herpes simplex virus type 2 antigen
Hassan et al. Immunological response and protection of mice immunized with plasmid encoding Toxoplasma gondii glycolytic enzyme malate dehydrogenase